Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal BetahistineGlobeNewsWire • 03/05/20
Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine ModelGlobeNewsWire • 02/25/20
Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing LossGlobeNewsWire • 12/30/19
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight GainGlobeNewsWire • 10/11/19
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development ProgramGlobeNewsWire • 09/13/19
Auris Medical Holding Ltd. (EARS) CEO Thomas Meyer on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/15/19
Auris Medical Holding AG (EARS) CEO Thomas Meyer on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 03/14/19